RxDoctor Payments Data

Robert Conner, DO

Geriatric Medicine · West Des Moines, IANPI 1447363700

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $240 of the $339 with a category attached, or 70.8%. Teva Pharmaceuticals USA, Inc. accounts for 68.7% of it on its own, with 3 other manufacturers making up the rest.

$339in general payments, 2019–2025

Across 7 payments — averaging $48.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$233
  • Urovant Sciences Inc$47
  • AstraZeneca$39
  • Sumitomo Pharma America, Inc.$20

What the payments were for

  • Food & beverage$24071%
  • Education$9929%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric medicine providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$649,976
Medicare patients
2,431
Services billed
12,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,344$400,954
Invega SustennaPaliperidone Palmitate54$185,182
JanuviaSitagliptin Phosphate493$145,688
XareltoRivaroxaban268$80,358
GemtesaVibegron328$79,956
JardianceEmpagliflozin257$77,613
MyrbetriqMirabegron317$74,796
Memantine Hcl1,084$52,008
BiktarvyBictegrav/Emtricit/Tenofov Ala12$50,959
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$34,874
Risperdal ConstaRisperidone Microspheres47$33,062
Lantus SolostarInsulin Glargine,hum.Rec.Anlog418$31,766
Gabapentin1,579$31,210
Divalproex Sodium277$27,540
Combivent RespimatIpratropium/Albuterol Sulfate52$26,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$20$79,956328 claims
AstraZenecaFarxiga, Breztri Aerosphere$39$41,703106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other geriatric medicine in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →